Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Epi-Stop

Financiado

Recapitulating and preventing epileptogenesis in early human brain network devel...

Epilepsy is one of the most common neurological disorders, yet current treatments fail to prevent seizures in more than a third of cases (~37%). Most drug targets focus on seizure suppression; however, these are symptoms of abnorm... ver más

31/03/2026

IMBA

184K€

Presupuesto del proyecto: 184K€

Líder del proyecto

INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-06

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023

I+D

Cerrada hace 1 año

0% 100%

1 Participantes

IMBA

183.60K€ | Lider

Proyectos interesantes

BRAINMOS Brain Mosaicism Matters: Organoids in focus to unveil mechan... 196K€ Cerrado

EpiNeuron Tracing human cortical neurons involved in epileptic process... 196K€ Cerrado

CONECTIF Commercial assessment of a novel protocol for epilepsy chara... 150K€ Cerrado

MENTE MultiscalE dynamics on high-order NeTworks applied to Epilep... 196K€ Cerrado

SAF2010-18586 GENETICA DE LAS EPILEPSIAS HUMANAS 220K€ Cerrado

EpiSen Senolytics repurposing in childhood refractory epilepsies 150K€ Cerrado

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 24 meses Fecha Inicio: 2024-03-06
Fecha Fin: 2026-03-31

Líder del proyecto

INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH

TRL 4-5

Presupuesto del proyecto 184K€

Descripción del proyecto Epilepsy is one of the most common neurological disorders, yet current treatments fail to prevent seizures in more than a third of cases (~37%). Most drug targets focus on seizure suppression; however, these are symptoms of abnormal developmental changes in the neural network. The processes that give rise to epileptic brain regions are summarized by the concept of epileptogenesis. Therefore, preventing epileptogenesis is critical for long-lasting seizure freedom. Studying epileptogenesis is challenging, as the developmental processes involved in it occur before birth during neurodevelopment itself. Recent progress in stem cell models, however, has the potential to change this. The Knoblich Lab pioneered the use of human cerebral organoids to model disease in-vitro, such as Tuberous Sclerosis (TSC). Cortical tubers are the source of drug-resistant epilepsy (DRE) in TSC, which our recent study (Eichmüller et al., Science 2022) uncovered to originate from a specific precursor cell type; CLIP cells. Strong preliminary evidence shows that pathological processes are occurring in TSC organoids which recapitulate epileptogenic electrical biomarkers called high frequency oscillations (HFOs). In this proposal I will utilise our brain organoid model to understand human circuit-level dysfunction in epilepsy and identify evidence-based causal treatment for epileptogenesis prevention. Therefore, I plan to classify stages of epileptogenesis in human brain TSC organoids using large-scale signal features and in-depth molecular characterizations to identify biomarkers for abnormal circuit initiation and progression. I will reveal stage-specific druggable targets for epileptogenesis and then test novel anti-epileptogenic compounds on pathological network activity prevention. Together, this project marks a change in the approach towards epileptic drug discovery to combat the significant socioeconomic burden of drug-resistant epilepsy.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores